Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinomaRobin Park, Christine H. Chung, Maria I. Poole et al.|Oral Oncology|2024Cited by 5
Data from Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck CancerRitu Chaudhary, Christine H. Chung, Graydon Moorhead et al.|Unknown|2026Cited by 0